Who Paid My Doc
Jeremy Jaffe
Abington, PA Medical Doctor
NPI 1982606182 CMS profile 1299698
1200 Old York Rd, Abington, PA 19001
General payments
$24,951
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jeremy Jaffe of Abington, PA is reported in the CMS Open Payments database as having received $24,951 across 1,106 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,956 | 131 | |
| 2024 | General | $3,651 | 154 | |
| 2023 | General | $4,657 | 215 | |
| 2022 | General | $5,735 | 243 | |
| 2021 | General | $3,695 | 175 | |
| 2020 | General | $1,632 | 77 | |
| 2019 | General | $2,626 | 111 |
Beside peers
- Jeremy Jaffe
- Pennsylvania median
- Middle half of Pennsylvania
- National median
In program year 2025, general payments to Jeremy Jaffe were reported at $2,956. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.
Show as a table
| Year | Jeremy Jaffe | Pennsylvania median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,626 | $156 | $46–$628 | $163 |
| 2020 | $1,632 | $109 | $33–$381 | $114 |
| 2021 | $3,695 | $125 | $35–$469 | $132 |
| 2022 | $5,735 | $136 | $40–$499 | $149 |
| 2023 | $4,657 | $147 | $46–$523 | $160 |
| 2024 | $3,651 | $156 | $46–$568 | $164 |
| 2025 | $2,956 | $168 | $50–$597 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 73 drugsPart D claims
8,582
Drug cost
$1,015,562
Branded share of claims
30.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycontin Oxycodone Hcl | Brand | 180 | $213,689 | |
| Xtampza Er Oxycodone Myristate | Brand | 143 | $120,547 | |
| Austedo Deutetrabenazine | Brand | 20 | $120,066 | |
| Relistor Methylnaltrexone Bromide | Brand | 29 | $66,136 | |
| Nucynta Tapentadol Hcl | Brand | 44 | $49,681 | |
| Ubrelvy Ubrogepant | Brand | 22 | $42,224 | |
| Movantik Naloxegol Oxalate | Brand | 100 | $42,208 | |
| Ztlido Lidocaine | Brand | 51 | $41,532 | |
| Oxycodone Hcl | Generic | 1,317 | $29,564 | |
| Nurtec Odt Rimegepant Sulfate | Brand | 18 | $29,189 |
The 10 drugs with the highest cost, of 73 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 79 billing codesPaid by Medicare
$875,298
Medicare patients
1,138
Services billed
27,424
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 39% | |
| Diabetes | 28% | |
| Ischemic heart disease | 28% | |
| Osteoporosis | 25% | |
| Chronic kidney disease | 22% | |
| COPD | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 154 | 1,577 | $1,231 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 121 | 10,020 | $1,014 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 36 | 37 | $284 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 169 | 274 | $79 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 23 | 122 | $8 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 23 | 55 | $5 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 16 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| XTAMPZA |
|
$600 | 143 | — |
| MOVANTIK |
|
$201 | 100 | — |
| ZTLido |
|
$132 | 51 | — |
| NURTEC ODT |
|
$92 | 18 | — |
| ZAVZPRET |
|
$92 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 16 in the dashboard with a free accountRecords
1,106 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.